Tests génétiques pour le cancer gastrique
After nearly ten years of development, tumor genetic testing has become the immediate need of a large number of cancer patients. The test report guidance provided by tumor genetic testing perfectly fits the development concept of precision medicine, and has penetrated into all aspects of the diagnosis and treatment of tumor patients. For patients, they can choose targeted drugs for precise treatment, avoid detours, and avoid unnecessary side effects. bitter.
État actuel du traitement ciblé du cancer gastrique
In most cases, surgery is still the main treatment for gastric cancer. However, the heterogeneity of gastric cancer is very strong, and its biological behavior is affected by the huge gene regulation in the cell. Therefore, only by classifying the essential characteristics of gastric cancer from the molecular level can early diagnosis and prognosis judgment of the tumeur be more reasonable and accurate , Application of molecular targeted drugs for individualized and precise treatment of patients.
À l'heure actuelle, les médicaments ciblés suivants ont été approuvés:
| Numéro de série | Target | drogue |
| 1 | HER2 | Trastuzumab (Trastuzumab, Herceptine) |
| 2 | VEGFR | Ramucirumab |
| 3 | NTRK | Larotrectinib (LOXO-101) |
| 4 | PD-1 | Pembrolizumab (K drug) |
| 5 | VEGFR-2 | Apatinib (Apatinib, Aitan) |
In addition, there are many other targeted drugs related to gastric cancer in clinical trials, such as drugs that block HER2: lapatinib (Tykerb ®), pertuzumab (Perjeta ®) and trastuzumab emtansine (Kadcyla ®). Drugs that block EGFR: Panitumumab (Victibi®) is a drug that targets EGFR that is being tested for gastric cancer.
The Global Oncologist Network reminds everyone that genetic testing is required before targeted therapy . Only by understanding the type of tumor gene mutation can a reasonable treatment plan be developed to benefit patients. In addition, in the selection of genetic testing technology, it is necessary to select the appropriate testing technology according to its corresponding target . Only by choosing products approved by the State Food and Drug Administration can the accuracy and reliability of the test results be guaranteed.
Comment les patients atteints d'un cancer gastrique choisissent-ils les tests génétiques?
The Global Oncologist Network reminds patients that cancer genetic testing and clinical treatment analysis are a systematic project that requires strong laboratory support, high-standard testing quality control and a high-level data analysis team. A good genetic test analysis can avoid the loss of treatment opportunities and save the lives of cancer patients. At present, there are dozens of genetic testing institutions on the market, and patients must carefully select genetic testing companies to ensure the accuracy of the test results.
Voici une technologie de test génétique approuvée par la FDA!
FoundationOne®CDx
FoundationOne®CDx a été approuvé par la FDA comme premier produit de diagnostic compagnon de type pan-tumoral . As a research tool, it assisted the discovery of countless scientific research results, and accumulated a large amount of data during this period. The current test coverage includes 324 genes and two molecular markers (MSI / TMB) that can predict the efficacy of immune checkpoint inhibitors. It can cover all solid tumors (except sarcome) and can directly correspond to 17 thérapies ciblées approuvées par la FDA!
For clinical evaluation of cancer genes, commonly used techniques include Sanger sequencing, mass spectrometry genotyping, fluorescence in situ hybridization (FISH) and immunohistochemical analysis (IHC). “Standard single marker detection” such as FISH, IHC and multi-gene hotspot detection (hotspot panel) can only find one or two types of clinically significant genetic abnormalities (such as only base substitutions). Studies have shown that the latest comprehensive next-generation sequencing technology for cancer comprehensive genetic testing can detect all four types of genetic abnormalities (base replacement; insertion and deletion; copy number variation and rearrangement), and is more accurate than traditional, standard tests.
Comment les patients atteints de cancer peuvent-ils subir le test FoundationOne® CDx?
En Chine, il s'agit d'un service d'analyse fourni par Dean Diagnostics. Global Oncologist Network peut aider les patients atteints de cancer à recevoir ce service, ou des tests génétiques pour une certification nationale faisant autorité. Global Oncologist Network, en tant que plate-forme de service nationale bien connue pour les patients atteints de cancer, a été Le centre d'oncologie et des experts bien connus du cancer travaillent en étroite collaboration pour organiser régulièrement de telles réunions d'échange médecin-patient à grande échelle et des conférences de vulgarisation scientifique pour aider les patients à se standardiser. et des plans de diagnostic et de traitement faisant autorité grâce à des consultations d'experts au pays et à l'étranger, et améliorer le taux de guérison. Nous déploierons également des efforts constants pour présenter en permanence les informations, la technologie, les experts, les médicaments, les essais cliniques, etc. de pointe sur la lutte contre le cancer, et nous nous efforcerons de fournir à plus de patients de meilleurs services anticancéreux.
CancerFax en tant que plate-forme de conseil et de services de diagnostic et de traitement du cancer bien connue, s'est engagée à fournir des services anticancéreux de première classe aux patients cancéreux nationaux, y compris la dernière technologie anticancéreuse et les meilleures ressources d'experts en cancérologie, mettant en place la plus grande tumeur centre de consultation et de conseil en Inde, et coopérez avec des centres de consultation et des experts renommés en matière de tumeurs aux États-Unis, en Chine, en Israël et en Europe pour devenir l'expert en conseil en diagnostic et traitement des tumeurs le plus fiable au monde.
